Genetic Variation in STAT4 Predicts Response to Interferon-α Therapy for Hepatitis B e Antigen-Positive Chronic Hepatitis B
Genetic Variation in STAT4 Predicts Response to Interferon-α Therapy for Hepatitis B e Antigen-Positive Chronic Hepatitis B
复制标题
STAT4 的遗传变异可预测干扰素-α 治疗乙型肝炎和抗原阳性慢性乙型肝炎的反应
DOI：
10.1002/hep.28423
复制
发表时间：
2016-04-01
期刊：
影响因子：
13.5
通讯作者：
Xu, Jianfeng
中科院分区：
文献类型：
--
作者：
Jiang, De-Ke;Wu, Xiaopan;Xu, Jianfeng
Interferon (IFN)-alpha is a first-line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus-related hepatocellular carcinoma. We aimed to determine whether this variant is associated with the response to IFN alpha treatment for hepatitis B e antigen (HBeAg)-positive CHB patients. We studied 466 HBeAg-positive CHB patients who received either IFN alpha-2b (n = 224) or pegylated IFN alpha-2a (n = 242) therapy for 48 weeks and were followed for an additional 24 weeks. The rate of sustained virologic response (SVR), defined as HBeAg seroconversion along with hepatitis B virus DNA level
